Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Tarsus Pharmaceuticals, Inc.’s reported figures.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s EBITDA?
- Tarsus Pharmaceuticals, Inc. (TARS) reported EBITDA of -$18.91M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s EBITDA changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s EBITDA increased by 13.2% year-over-year, from -$21.78M to -$18.91M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s EBITDA has grown at a 55.5% compound annual growth rate (CAGR), from -$11.85M to -$69.27M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude